<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02209363</url>
  </required_header>
  <id_info>
    <org_study_id>4120</org_study_id>
    <nct_id>NCT02209363</nct_id>
  </id_info>
  <brief_title>Cognition and Obstructive Sleep Apnea in Parkinson's Disease, Effect of Positive Airway Pressure Therapy</brief_title>
  <acronym>COPE-PAP</acronym>
  <official_title>Cognition and Obstructive Sleep Apnea in Parkinson's Disease, Effect of Positive Airway Pressure Therapy (COPE-PAP Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Thoracic Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cognitive dysfunction (impaired memory, thinking, etc) frequently occurs in Parkinson's&#xD;
      disease (PD), often progresses to dementia, and profoundly affects quality of life.&#xD;
      Obstructive sleep apnea (OSA) is a common disorder in the general population that is&#xD;
      treatable with positive airway pressure (PAP) therapy. It is known to impair cognitive&#xD;
      function, but whether treatment improves cognitive function is less clear. When already&#xD;
      affected by a degenerative process like PD, the brain might be more vulnerable to the effects&#xD;
      of OSA, and more responsive to OSA treatment. To date, OSA has not been recognized as a&#xD;
      significant factor in PD. In preliminary work in PD patients, the investigators have found an&#xD;
      association between OSA and poor cognition, and cognitive improvement with PAP therapy. The&#xD;
      investigators now wish to more rigorously evaluate the effect of OSA treatment on cognitive&#xD;
      function in PD in a randomized controlled trial. The investigators primary objective is to&#xD;
      assess, in PD patients with OSA and cognitive deficit, the effect of OSA treatment on global&#xD;
      cognitive function. The investigators will also assess other non-motor symptoms of PD,&#xD;
      quality of life, and specific domains of neurocognitive function. PD patients will be&#xD;
      recruited from the McGill Movement Disorders Clinic and other Quebec Parkinson Network&#xD;
      Centres. Participants will need to have evidence of cognitive deficit and presence of OSA on&#xD;
      screening diagnostic polysomnography (sleep study). Ninety subjects will be randomly assigned&#xD;
      to PAP or nasal dilator strips. Detailed neuropsychological testing and other measurements&#xD;
      (including quality of life) will be done at baseline, 3 months and 6 months. At the end of&#xD;
      the study period, subjects will have polysomnography on their respective treatment to assess&#xD;
      efficacy with respect to OSA treatment. This study may demonstrate that a non-pharmacologic&#xD;
      intervention has the potential to have a marked beneficial impact on cognitive function and&#xD;
      quality of life in a significant proportion of PD patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in global cognitive function</measure>
    <time_frame>6 months</time_frame>
    <description>Montreal Cognitive Assessment (MoCA) - score range 0-30.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in non-motor symptoms of Parkinson's disease</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>MDS-UPDRS part 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>PDQ-39</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in specific domains of neurocognitive function</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Detailed neurocognitive assessment including attention and working memory, executive function, language, memory and visuospatial function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in global cognitive function</measure>
    <time_frame>3 months</time_frame>
    <description>Montreal Cognitive Assessment (MoCA)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>REM sleep behaviour disorder</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Severity and frequency of symptoms in last 3 months will be assessed.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Positive airway pressure (PAP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Auto-adjusting positive airway pressure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nasal dilator strips</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>auto-adjusting positive airway pressure</intervention_name>
    <description>nightly use for 6 months</description>
    <arm_group_label>Positive airway pressure (PAP)</arm_group_label>
    <other_name>auto-CPAP</other_name>
    <other_name>APAP</other_name>
    <other_name>auto-PAP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nasal dilator strips</intervention_name>
    <description>nightly use for 6 months</description>
    <arm_group_label>nasal dilator strips</arm_group_label>
    <other_name>Breathe-right</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Parkinson's disease as perMDS criteria&#xD;
&#xD;
          -  Evidence of cognitive dysfunction (clinical impression of mild cognitive impairment&#xD;
             and MOCA &lt;=27)&#xD;
&#xD;
          -  Presence of OSA (apnea-hypopnea index RDI â‰¥ 15/h) on screening diagnostic&#xD;
             polysomnography (PSG)&#xD;
&#xD;
          -  Stable regimen of anti-PD medication for 1 month prior&#xD;
&#xD;
          -  Adequate knowledge of English or French for completion of study assessment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Oxygen saturation &lt;75% for &gt;10% of the diagnostic polysomnography as this should lead&#xD;
             to active PAP treatment&#xD;
&#xD;
          -  Other major neurological disorder&#xD;
&#xD;
          -  Unstable cardiac disease, uncontrolled hypertension, or diabetes&#xD;
&#xD;
          -  Active cancer or other disorder with an expected survival &lt; 6 months&#xD;
&#xD;
          -  Active treatment of OSA (prior diagnosis of OSA will constitute an exclusion criterion&#xD;
             only if the patient is currently being treated for the OSA)&#xD;
&#xD;
          -  Significant vision or hearing impairment that could affect performance on&#xD;
             neurocognitive assessment tasks.&#xD;
&#xD;
          -  Latex allergy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Kaminska, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Hospital and Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 31, 2014</study_first_submitted>
  <study_first_submitted_qc>August 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2014</study_first_posted>
  <last_update_submitted>August 28, 2021</last_update_submitted>
  <last_update_submitted_qc>August 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>Marta Kaminska</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>OSA</keyword>
  <keyword>CPAP</keyword>
  <keyword>cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

